Accepted: 17 January 2018
DOI: 10.1111/epi.14486
SUPPLEMENT ARTICLE
Intravenous brivaracetam in status epilepticus: A retrospective
single‐center study
Gudrun Kalss | Alexandra Rohracher | Markus Leitinger | Georg Pilz |
Helmut F. Novak | Caroline Neuray | Rudolf Kreidenhuber | Julia Höfler |
Giorgi Kuchukhidze | Eugen Trinka
Department of Neurology, Christian
Doppler Clinic, Paracelsus Medical
University, Salzburg, Austria
Correspondence
Eugen Trinka, Department of Neurology,
Christian Doppler University Hospital,
Paracelsus Medical University, Salzburg,
Austria.
Email: e.trinka@salk.at
Summary
Brivaracetam (BRV) is a high‐affinity synaptic vesicle glycoprotein 2A ligand
that is structurally related to levetiracetam (LEV). Compared to LEV, its affinity
to the ligand is >10%‐30% higher. Due to its more lipophilic characteristics, it
might have a quicker penetration across the blood‐brain barrier and potentially
also a stronger anticonvulsant effect. Thus, we aimed to explore its usefulness in
the treatment of status epilepticus (SE). We retrospectively assessed treatment
response and adverse events in adjunctive treatment with intravenous BRV in
patients with SE from January 2016 to July 2017 at our institution. Seven patients
aged median 68 years (range = 29‐79) were treated with intravenous BRV. Three
patients had SE with coma and four without. SE arose de novo in two patients;
etiology was remote symptomatic in four patients and progressive symptomatic in
one patient. The most frequent etiology was remote vascular in two patients.
BRV was administered after median four antiepileptic drugs (range = 2‐11). Time
of treatment initiation ranged from 0.5 hours to 105 days (median = 10.5 hours).
Immediate clinical and electrophysiological improvement was observed in two
patients (29%). Median loading dose was 100 mg intravenously over 15 minutes
(range = 50‐200 mg), titrated up to a median dose of 100 mg/d (range = 100‐
300). Median Glasgow Outcome Scale score was 3 (range = 3‐5), with an
improvement in 86% of patients compared to admission. We observed no adverse
events regarding cardiorespiratory function. BRV might have potential as a novel
antiepileptic drug in early stages of SE. Its potential may lie its ability to cross
the blood‐brain barrier more quickly than LEV and its favorable safety profile.
Prospective studies for the use of BRV in SE are required.
KEYWORDS
EEG, epilepsy, intensive care unit, levetiracetam
---------------------------------------------------------------------------------------------------------------------------------------------------------------------This is an open access article under the terms of the Creative Commons Attribution-Noncommercial License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited and is not used for commercial purposes.
© 2018 The Authors. Epilepsia published by Wiley Periodicals, Inc. on behalf of International League Against Epilepsy
228
|
wileyonlinelibrary.com/journal/epi
Epilepsia. 2018;59(S2):228–233.
KALSS
1
|
ET AL.
229
| INTRODUCTION
Status epilepticus (SE) is one of the most important neurological emergencies. It is associated with high morbidity
and mortality.1–3 SE is defined as the “failure of mechanisms responsible for seizure termination or the initiation
of mechanisms that lead to abnormally prolonged seizures
(t1), which might have long‐term consequences (t2),
including neuronal death, neuronal injury and alteration of
neuronal networks depending on seizure type and duration.”4 The pathophysiological correlate of seizure perpetuation might be the imbalance between the inhibitory
transmitter γ‐aminobutyric acid (GABA) and the excitatory
transmitter glutamate. In the early stages of SE, GABAergic drugs, such as benzodiazepines, are most effective in
seizure termination. With ongoing seizure activity, GABAA
receptors in the postsynaptic membrane are internalized
and GABAergic drugs become less efficacious. In contrast,
N‐methyl‐D‐aspartate receptor receptors are increasingly
expressed at the postsynaptic membrane, resulting in seizure perpetuation by offering more glutamate binding
sites.5
Brivaracetam (BRV) is a high‐affinity synaptic vesicle
glycoprotein 2A ligand that is structurally related to levetiracetam (LEV). Compared to LEV, its affinity to the
ligand is >10%‐30% higher.6 BRV has linear and predictable pharmacokinetics. It is rapidly and almost completely absorbed after oral intake, with peak serum
concentrations after 0.5‐2 hours. The volume of distribution
is 0.5 L/kg, and <20% of the drug is protein bound; t½ is
about 9 hours. The elimination of BRV is dependent on
CYP2C8 and to a lesser degree on CYP3A4 and
CYP2C19. Strong inducers increase the hydroxylation and
decrease the serum concentrations by up to 50%. In
patients with liver disease, the clearance may be reduced
by 25%‐35% and t½ is prolonged up to 17 hours.7–9 In
patients with renal dysfunction, the dose has to be reduced
accordingly, due to the renal elimination of BRV.10 Steady
state is reached after 2 days. In healthy men, BRV Cmax
serum levels reached 3.5 μg/mL, 7.7 μg/mL, and 13.3 μg/
mL under a treatment regime of BRV 200 mg/d, 400 mg/d,
and 800 mg/d, respectively, after 14 days of intake. Mean
BRV levels in healthy men were between 2.02 and
2.06 μg/mL under treatment with BRV 200 mg/d and
between 1.06 and 1.15 μg/mL under BRV 100 mg/d. The
good water solubility allows also for an intravenous (IV)
formulation.11 Due to its more lipophilic characteristics,
BRV penetrated the blood‐brain barrier in in vitro models
more rapidly than LEV, which might translate into higher
efficacy in emergency situations.12 Therefore, the inhibition
of transmitter release and the fast penetration through the
Key Points
• BRV administration IV 100 mg bolus over
15 minutes in SE was safe with respect to cardiovascular side effects
• BRV was successful in ceasing SE in four of
seven patients in an early stage
blood‐brain barrier reveal new treatment possibilities in
early stages of SE.
On the one hand, there is only sparse data on the use of
BRV in SE. A multicenter case series on the use of BRV
in SE included 11 patients from two German hospitals and
documented a treatment response in 27%.13,14 On the other
hand, postmarketing studies suggest a simple usage and
favorable retention rates of the drug.13,15
Here, we report a single case series on the use of IV
BRV in SE to evaluate safety and efficacy of the adjunctive treatment with IV BRV in SE.
2
| MATERIALS AND METHODS
We analyzed all patients who received IV BRV as an add‐
on treatment in early, established, refractory, and super‐
refractory SE and who were referred to the neurological
emergency room, the neurological intensive care unit
(NICU), or the neurological normal ward in Salzburg, Austria from January 2016 to July 2017. We collected data on
the underlying etiology, SE type, and duration of SE. We
analyzed duration of hospitalization and NICU treatment,
number and sequence of administered antiepileptic drugs
(AEDs) before initiation of BRV, treatment response to
BRV within 1 hour and >24 hours, outcome of SE, and
adverse effects after add‐on treatment with BRV.
The diagnosis of SE was made clinically by the physician in the emergency setting and by using electroclinical
criteria for nonconvulsive SE (NCSE) proposed by the
Salzburg consensus criteria on SE.16 We classified SE subtypes according to the proposal of the International League
Against Epilepsy taskforce on SE.4 We distinguished
between SE type A with prominent motor symptoms (including tonic–clonic SE, myoclonic SE, focal motoric SE,
tonic SE, and hyperkinetic SE) and type B without prominent motor symptoms (NCSE with or without coma).4
Etiology was classified as symptomatic when a cause was
identified and as cryptogenic in the case of unknown cause.
Symptomatic SE was further subclassified into acute symptomatic, remote symptomatic, or progressive symptomatic SE.
230
|
KALSS
Mortality risk was calculated by the Status Epilepticus
Severity Score17 (cutoff level for unfavorable outcome = 3
points) and the Epidemiology‐Based Mortality Score in
Status Epilepticus18 (cutoff level for unfavorable outcome
= 64 points).
Treatment followed the international consensus
approach.19 In stage I, benzodiazepines were administrated.
In stage II, intravenous AEDs were administrated (eg,
LEV, valproate, phenytoin, lacosamide, or BRV). In case
of ongoing seizure activity with impaired consciousness,
stage III treatment was initiated with propofol and midazolam. Super‐refractory SE was defined as persistent seizure
activity for >24 hours. At this stage, treatment options like
magnesium (Mg2+), other AEDs, and ketamine were
administered in comatose patients according to the physician in charge.
Blood samples including hemogram, C‐reactive protein,
basic metabolic panel including electrolytes, blood urea,
nitrogen, creatinine, glucose, liver enzymes, and levels of
administered AEDs were taken regularly. For those patients
referred to the NICU, these samples were taken daily and
blood gas analysis was performed at least twice a day.
2.1
| Statistics
Descriptive statistics were calculated using Office Excel
2016 (Microsoft, Redmond, WA, USA). We analyzed median, range, and percentages due to the lopsided distribution.
Due to the small sample size, statistical analyses between
responders and nonresponders were not performed.
2.2 | Standard protocol approvals,
registrations, and patient consent
This study is a retrospective documentation of individual
treatment decisions without research approach in an emergency setting. Individual treatment decisions are by Austrian law the responsibility of the operating physician. Due
to the retrospective character of this study, it did not
require ethics committee approval according to the Austrian
Law on Research.
3
| RESULTS
Seven patients (six women) received IV BRV between January 2016 and July 2017. Median age was 68 years (range
= 29‐79). Three patients had SE with coma, and four
patients had SE without coma. On the bidirectional axis,
four patients had SE type A with prominent motor symptoms and three patients had SE type B without prominent
motor symptoms (NCSE). Among the patients with prominent motor symptoms, one patient suffered from tonic‐
ET AL.
clonic status epilepticus, one from myoclonic SE with
coma, and two from epilepsia partialis continua. Among
the three patients with NCSE, only one was in coma. The
other two patients had aphasic status and aura continua,
one each.
Two patients fulfilled the criteria of established SE, one
had refractory SE, and three had super‐refractory SE. SE
was going on for >1 week in all super‐refractory SE
patients (median = 15 days, range = 9‐168).
SE occurred de novo in one patient due to hypoxic
brain injury. Five patients had a remote symptomatic and
one a progressive symptomatic cause. The most frequent
etiology was remote vascular (in two patients). The other
five patients suffered from hypoxia, mitochondrial disease,
lissencephaly, hypomelanosis of Ito, and brain abscess. For
further details on patients’ demographics see Table 1.
BRV was administered in median after four (range = 2‐
11) AEDs. Time of treatment initiation ranged from
0.5 hours to 105 days (median = 10.5 hours). Median loading dose was 100 mg (range = 50‐200 mg/d) IV over
15 minutes, titrated up to a median daily dose of 100 mg/d
(range = 100‐300).
Immediate clinical improvement was documented in
two patients (29%), and early electrophysiological cessation
of SE on surface electroencephalography (EEG) was
observed in three patients (43%). In two of them, BRV
administration and cessation of SE was documented during
the EEG investigation. However, one of these three patients
relapsed within 24 hours and was considered a nonresponder therefore.
In one BRV responder, SE was resolved before the
EEG. In the other BRV responders, cessation of SE in
EEG was documented after median 25 hours (range = 0.5–
48). One showed periodic lateralized discharges with superposed evolution pattern (lateralized periodic discharges)
over the right parietal region (Figure S1). The third showed
generalized rhythmic delta activity, and the fourth displayed evolution pattern over the right frontal region.
The four BRV responders had early stage SE (two established SE) when BRV was loaded. Two of them had BRV in
their premedication and therefore received BRV as stage II
treatment to address the question of possible withdrawal seizures. Patient 3 had LEV in her premedication. However, it
had been reduced by 250 mg (from 1500 to 1250 mg)
1 week before. One of the BRV responders had aura continua. This patient failed three AEDs, among them LEV with
daily relapses after initial response. BRV treatment was initiated in this patient 15 minutes prior to valproate within 1
hour after his latest SE relapse (Data S2 and S3: clinical
course BRV responders and BRV nonresponders).
Outcome after SE was severe disability in five patients.
One of the BRV responders had no impairment; the other
three responders regained their previous level of disability,
KALSS
|
ET AL.
T A B L E 1 Demographical data and SE classification in
brivaracetam responders and nonresponders
Total
Responders
Nonresponders
n (%)
7
4
3
Women
6
3
3
General anesthesia
2
0
2
Preexisting epilepsy
5
3
2
Acute symptomatic
1
0
1
Remote symptomatic
5
4
1
Progressive symptomatic
1
0
1
2
1
1
Type of SE
Etiology
Cerebrovascular
Mitochondrial disorder
1
0
1
Lissencephaly
1
1
0
CNS infection
1
1
0
Hypoxia
1
0
1
Hypomelanosis of Ito
1
1
0
Tonic–clonic SE (A.1)
1
1
0
Myoclonic SE with
coma (A.2.a)
1
1
0
EPC (A.3.b)
2
1
1
NCSE with coma (B.1)
1
0
1
Aura continua (B.2.b.a)
1
1
0
Aphasic status (B.2.b.b)
1
0
1
GPDs
1
0
1
LPDs
3
1
2
Evolution pattern
1
1
0
Generalized rhythmic delta
1
1
0
EEG resolved
1
1
0
SE classification4
EEG pattern
CNS, central nervous system; EEG, electroencephalographic; EPC, epilepsia
partialis continua; GPD, generalized periodic discharge; LPD, lateralized periodic discharge; NCSE, nonconvulsive SE; SE, status epilepticus.
which was severe. Glasgow Outcome Scale overall was
median 3 (range = 3‐5), with an improvement in 83% of
patients compared to admission. No case of death was documented.
Status Epilepticus Severity Score was true negative in
three patients and Epidemiology‐Based Mortality Score in
Status Epilepticus score in four, yielding a negative predictive value 100% each. Positive predictive value was 0 each.
Three of the patients were referred to the NICU (median
duration = 18 days, range = 12‐41). All of them were
BRV nonresponders. No patient was catecholamine dependent on referral or after BRV administration. Mean hospitalization was 17 days (range = 0‐187). Hospitalization in
231
BRV responders was median 10 days (range = 0‐17), compared to median 87 days (range = 30–187) in BRV nonresponders.
No adverse events in respect to cardiorespiratory function were documented related to BRV administration. One
patient had hair loss and autoaggression later in the course.
Levels of coadministered AEDs were taken regularly, without documented changes after add‐on treatment with BRV.
For dosing of BRV and outcomes see Table 2.
4
| DISCUSSION
Literature on the use of IV BRV in human SE is sparse. In
this case series, BRV responders were treated earlier in the
course of SE as opposed to BRV nonresponders. They
responded to treatment within the first 2 hours after administration. One of the patients with initial EEG response to
BRV relapsed within 24 hours and was considered therefore a nonresponder. In all of the BRV responders, we
were able to document clinical and electrophysiological
cessation of SE. In one patient, BRV was administered during EEG and clinical and EEG improvement was documented at the time. The other three responders showed fast
clinical response to BRV. EEG response was documented
at the latest within 48 hours, because during night shift and
weekends the EEG technician is on call. Therefore, emergency EEGs are only performed if there is clinical evidence
of ongoing seizure activity.
We documented a synergistic effect of valproate and
BRV in one LEV nonresponder. None of our patients had
either LEV or BRV withdrawal seizures. BRV Responder 3,
whose BRV dose was reduced by 250 mg 1 week before, is
cared for by her mother at home. A mistake in AED intake is
highly unlikely. We did not consider this dose reduction causal for her SE, as she had remitting SE in her history. The
rapid treatment response might be due to the rapid penetration of BRV across the blood‐brain barrier.11 Furthermore,
the effect of synaptic vesicle glycoprotein 2A modulation on
GABAergic neurotransmitter release might suggest a high
effectiveness of BRV in early stages of SE.
Due to the fast treatment response and the lack of cardiorespiratory adverse effects, the referral to the intensive
care unit was not needed in all of the BRV responders. Early
successful treatment with BRV did not only lead to shorter
hospitalization but also to regaining the premorbid functional
status as documented by Glasgow Outcome Scale.
5
| CONCLUSION
BRV might have potential as emergency treatment in the
early SE stages. In this small series, BRV had a favorable
232
|
KALSS
ET AL.
T A B L E 2 Dosing of BRV and outcomes of status epilepticus after treatment
Total
Median
Responders
Range
Age, y
68
Hospitalization, d
17
NICU, d
18
12‐41
100
50‐200
BRV loading dose, mg, IV
BRV loading dose, at h
BRV daily dose, mg, IV
10.5
200
29‐79
0‐187
0.5‐2520
100‐300
Median
Nonresponders
Range
Median
Range
53
29‐79
68
32‐75
10
0‐17
87
30‐187
0
18
12‐41
100
50‐200
0.5‐10.5
120
120‐2520
100‐200
200
200‐300
0
100
1.5
150
50‐100
AEDs, n
4
2‐11
2.5
2‐4
4
4‐11
GOS
3
3‐5
3
3‐5
3
3‐4
AED, antiepileptic drug; BRV, brivaracetam; GOS, Glasgow Outcome Scale; IV, intravenous route; NICU, neurological intensive care unit.
safety profile and a rapid onset of action. Prospective studies for the use of BRV in early SE are required.
DISCLOSURE OF CONFLICTS OF INTEREST
G.Ka. received travel support from UCB, Eisai, and
Cyberonics. A.R. received travel support and speaker honoraria from Eisai. M.L. received travel grants from Medtronic
and UCB and personal fees from EVER Neuro Pharma.
H.F.N. received speaker honoraria from Baxter Austria,
Astellas Pharma, SCS‐Angelini Pharmaceuticals, Fresenius
Medical Care Austria, and Orion Pharma, compensation
from UCB for clinical medication monitoring, and a travel
grant from Fresenius Kabi Austria. J.H. received speaker
honoraria from UCB and travel grants from UCB, Eisai, and
Gerot‐Lanach. E.T. is a payed consultant to UCB, Eisai,
Bial, Medtronic, EVER Neuro Pharma, Biogen Idec, and
Sunovion; he or his institution received research funding
from GSK, Biogen Idec, Novartis, Red Bull, and UCB and
speaker honoraria from GSK, Boehringer Ingelheim, Eisai,
Bial, Cyberonics, Sanofi‐Aventis, the Austrian Science
Fund, Jubilaeumsfond der Oesterreichischen Nationalbank,
and the European Union. The other authors have no conflicts
of interest to report. We confirm that we have read the Journal′s position on issues involved in ethical publication and
affirm that this report is consistent with those guidelines.
REFERENCES
1. Neligan A, Shorvon SD. Frequency and prognosis of convulsive
status epilepticus of different causes: a systematic review. Arch
Neurol. 2010;67:931–40.
2. Logroscino G, Hesdorffer DC, Cascino G, Annegers JF, Hauser
WA. Short‐term mortality after a first episode of status epilepticus. Epilepsia. 1997;38:1344–9.
3. Logroscino G, Hesdorffer DC, Cascino G, et al. Mortality after a
first episode of status epilepticus in the United States and Europe.
Epilepsia. 2005;46(suppl 11):46–8.
4. Trinka E, Cock H, Hesdorffer D, et al. A definition and classification of status epilepticus—report of the ILAE Task Force
on Classification of Status Epilepticus. Epilepsia. 2015;56:1515
–23.
5. Chen JW, Wasterlain CG. Status epilepticus: pathophysiology and
management in adults. Lancet Neurol. 2006;5:246–56.
6. Gillard M, Fuks B, Leclercq K, Matagne A. Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat,
mouse and human brain: relationship to anti‐convulsant properties. Eur J Pharmacol. 2011;664:36–44.
7. von Rosenstiel P. Brivaracetam (UCB 34714). Neurotherapeutics.
2007;4:84–7.
8. Stockis A, Sargentini-Maier ML, Horsmans Y. Brivaracetam disposition in mild to severe hepatic impairment. J Clin Pharmacol.
2013;53:633–41.
9. Mumoli L, Palleria C, Gasparini S, et al. Brivaracetam: review of
its pharmacology and potential use as adjunctive therapy in
patients with partial onset seizures. Drug Des Devel Ther.
2015;9:5719–25.
10. Sargentini-Maier ML, Sokalski A, Boulanger P, Jacobs T, Stockis
A. Brivaracetam disposition in renal impairment. J Clin Pharmacol. 2012;52:1927–33.
11. Nicolas JM, Hannestad J, Holden D, et al. Brivaracetam, a selective high‐affinity synaptic vesicle protein 2A (SV2A) ligand with
preclinical evidence of high brain permeability and fast onset of
action. Epilepsia. 2016;57:201–9.
12. Brandt C, May TW, Bien CG. Brivaracetam as adjunctive therapy for the treatment of partial‐onset seizures in patients with epilepsy: the current evidence base. Ther Adv Neurol Disord.
2016;9:474–82.
13. Steinig I, von Podewils F, Moddel G, et al. Postmarketing
experience with brivaracetam in the treatment of epilepsies: a
multicenter
cohort
study
from
Germany.
Epilepsia.
2017;58:1208–16.
14. Strzelczyk A, Steinig I, Willems LM, et al. Treatment of refractory and super‐refractory status epilepticus with brivaracetam: a
cohort study from two German university hospitals. Epilepsy
Behav. 2017;70:177–81.
15. Ryvlin P, Werhahn KJ, Blaszczyk B, Johnson ME, Lu S. Adjunctive brivaracetam in adults with uncontrolled focal epilepsy:
results from a double‐blind, randomized, placebo‐controlled trial.
Epilepsia. 2014;55:47–56.
KALSS
|
ET AL.
16. Leitinger M, Beniczky S, Rohracher A, et al. Salzburg consensus
criteria for non‐convulsive status epilepticus—approach to clinical
application. Epilepsy Behav. 2015;49:158–63.
17. Rossetti AO, Logroscino G, Milligan TA, Michaelides C, Ruffieux C, Bromfield EB. Status Epilepticus Severity Score
(STESS): a tool to orient early treatment strategy. J Neurol.
2008;255:1561–6.
18. Leitinger M, Holler Y, Kalss G, et al. Epidemiology‐Based Mortality Score in Status Epilepticus (EMSE). Neurocrit Care.
2015;22:273–82.
19. Trinka E, Höfler J, Leitinger M, Rohracher A, Kalss G, Brigo F.
Pharmacologic treatment of status epilepticus. Expert Opin Pharmacother. 2016;17:513–34.
233
SUPPORTING INFORMATION
Additional supporting information may be found online in
the Supporting Information section at the end of the article.
How to cite this article: Kalss G, Rohracher A,
Leitinger M, et al. Intravenous brivaracetam in status
epilepticus: A retrospective single‐center study.
Epilepsia. 2018;59(S2):228–233. https://doi.org/
10.1111/epi.14486